The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Tandem Meetings 2023 | LBA: Phase III study of Iomab-B prior to allogeneic transplantation vs conventional care in R/R AML
Rajneesh Nath, MD, Banner MD Anderson Cancer Center, Gilbert, AZ, discusses the findings from the Phase III SIERRA trial (NCT02665065) that randomized elderly patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) to Iomab-B followed by hematopoietic cell transplantation (HCT) or conventional care followed by HCT depending on patient eligibility. The study also allowed crossover to the Iomab-B arm if patients in the conventional care arm did not achieve complete remission (CR). The study met its primary endpoint of durability of CR at six months, and reported improved one-year survival rates in the Iomab-B arm. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Actinium – Consultant; Incyte – Advisory board
